[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [QUIET] · [BUSINESS]

2 clusters · 6 sources · 3 days · First seen · Last updated

FDA review delay for Novo Nordisk hemophilia drug

Overview

The U.S. Food and Drug Administration (FDA) has extended its review of Novo Nordisk’s experimental drug denecimig, a bispecific antibody intended to treat hemophilia A.

Novo Nordisk reported that the delay is due to ongoing remediation work at a manufacturing facility rather than concerns regarding the drug’s safety or clinical efficacy. The company stated that these manufacturing issues do not affect its existing medicines or its 2026 financial forecast. While the FDA has not provided a new timeline for a regulatory decision, Novo Nordisk maintains its goal of a U.S. launch in the first half of 2027.

Entities

Novo Nordisk · denecimig · FDA · U.S. Food and Drug Administration · US FDA

Timeline

  1. [BUSINESS] 2 sources
    Novo Nordisk Denecimig review extended by FDA

    The FDA has extended its review of Novo Nordisk’s Hemophilia A drug candidate, Denecimig, due to production facility issues, with a market launch still targeted for early 2027.

  2. [BUSINESS] 4 sources
    Novo Nordisk faces FDA delay for hemophilia A drug denecimig

    The FDA has delayed its decision on Novo Nordisk’s hemophilia A drug, denecimig, due to manufacturing remediation, though the company maintains its 2027 launch goal and 2026 financial outlook.

Sources

4investors.de · finanzen.ch · it-boltwise.de · medicaldialogues.in · newsable.asianetnews.com · sharedeals.de